<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02491515</url>
  </required_header>
  <id_info>
    <org_study_id>IRB9-2</org_study_id>
    <nct_id>NCT02491515</nct_id>
  </id_info>
  <brief_title>Effects of Denosumab Therapy for Japanese</brief_title>
  <official_title>Effects of Denosumab Therapy for Japanese Osteoporotic Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tomidahama Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tomidahama Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators would like to analyze the bone mineral density (BMD) , bone
      turnover makers, and fracture prevention effects of denosumab in Japanese patients under
      clinical practice. The participants are treated in the investigators hospital, who are under
      severe osteoporotic condition.

      The main objective of this study is to investigate effects of denosumab. The researchers also
      investigate the effects of Effects of previous osteoporotic therapy to denosumab treatment.
      In this study, the investigators analyse the determinants of subsequent BMD increase and
      fracture preventing effect by teriparatide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Registry criteria: Patients treated in the investigators hospital using denosumab. Enrolled
      patients are severe osteoporosis; more than two previous osteoporotic fractures, low BMD (&lt;
      young adult mean 65%).

      Interventions: blood analyses and dual-energy X-ray absorptiometry (DXA) every 4 months
      Informed consent: Written informed consent will be obtained. Sample size: Five-hundreds
      participants
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>BMD increase by denosumab in Japanese</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>The investigators evaluate BMD increase by denosmab in Japanese patients.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The determinants related to BMD increase and fracture prevention for denosumab treatment</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>The investigators evaluated lumbar and femoral neck BMD. The investigators evaluated baseline patients characteristics. The investigators will evaluate the relationship between BMD increase or fracture and patients characteristics using univariate and multivariate analysis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effects of previous therapy to denosumab</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>The investigators evaluate effects of previous osteoporosis treatment to denosumab in BMD increase and bone turnover marker response using univariate and multivariate analysis.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Osteoporosis</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>every 6 month injection</description>
    <other_name>Prolia</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Osteoporotic patients who admit to our hospital
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoporotic patients

        Exclusion Criteria:

          -  cancer, hypercalcemia, etc (i.e. patients who could not use denosumab)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>45 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rui Niimi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Tomidahama Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rui Niimi, MD</last_name>
    <phone>+81593650023</phone>
    <email>furikakefuri@hotmail.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Tomidahama Hospital</name>
      <address>
        <city>Yokkaichi</city>
        <state>Mie</state>
        <zip>510-8008</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rui Niimi, MD, PhD</last_name>
      <phone>(81)-59-365-0023</phone>
      <email>furikakefuri@hotmail.co.jp</email>
    </contact>
    <investigator>
      <last_name>Rui Niimi, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 27, 2015</study_first_submitted>
  <study_first_submitted_qc>July 2, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2015</study_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Tomidahama Hospital</investigator_affiliation>
    <investigator_full_name>Toshihiko Kono</investigator_full_name>
    <investigator_title>Head of Hospital</investigator_title>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>BMD</keyword>
  <keyword>denosumab</keyword>
  <keyword>previous therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

